New award for bortezomib vials with fresenius kabi. Ordering period is 03-11-2023 through 03-10-2024 with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79723D0013
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 91% complete
IDV ceiling
$2,237,072.60
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The National Acquisition Center (civilian agency under GSA) awarded a single-award indefinite-delivery contract to Fresenius Kabi, LLC on March 11, 2023, for bortezomib vials, with a ceiling value of $2,237,072.60 and an ultimate completion date of March 10, 2027.

The contract carries no set-aside designation. The ordering period runs March 11, 2023 through March 10, 2024, with four one-year options. The originating pre-solicitation was posted October 27, 2022.

A modification dated April 2026 incorporated Section 5 of Executive Order 14398 (Clause 52.222-90), addressing discrimination by federal contractors, into the contract.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00010 · Modification to incorporate section 5 of EO 14398, clause 52.222-90, addressing DEI discrimination by federal contractors (APR 2026), into the contract. $0
Exercise an Option P00009 · This modification is issued to exercise the 3RD option year for bortezomib vials under contract 36E79723D0013 with fresenius kabi, LLC for the period of… $0
Add Subcontract Plan P00008 · Incorporate fresenius kabi, LLC 2026 small business subcontracting plan 01/01/2026 - 12/31/2026 $0
Exercise an Option P00007 · Exercise 1ST option year for bortezomib vials with fresenius kabi EFF. 03-11-25 through 03-10-26 $0
Add Subcontract Plan P00006 · Incorporate 2025 subk small business subcontracting plan $0
Supplemental Agreement for work within scope P00005 · 52.212-4(C) contract terms and conditions - changes update to cost recovery fee (CRF) and submission of quarterly sales reports for 36E79723D0013 fresenius kabi… $0
Exercise an Option P00004 · This modification is issued to exercise the 1ST option year for bortezomib vials under contract 36E79723D0013 with fresenius kabi for the period of 3/11/2024… $0
Add Subcontract Plan P00003 · Modification 00003 is issued to incorporate fresenius kabi, LLC 2024 subcontracting plan $0
Other Administrative Action P00002 · Incorporation of drug supply chain security act (DSCSA) language $0
Add Subcontract Plan P00001 · Incorporate 2023 subcontracting plan with fresenius kabi, LLC for bortezomib effective 01/01/2023 through 12/31/2023. $0
Original award $0
Show all 11

Quick answers

Who was awarded contract 36E79723D0013?

36E79723D0013 was awarded to Fresenius Kabi, LLC by National Acquisition Center (Headquarters) on March 11, 2023.

How much is contract 36E79723D0013 worth?

36E79723D0013's own ceiling is $2,237,073.

Who can order from contract 36E79723D0013?

36E79723D0013 is a single award indefinite delivery contract.

Was contract 36E79723D0013 competed?

The extent of competition for 36E79723D0013 was full and open competition. The government received 2 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV